By Counterforce Health Team in Evkeeza (evinacumab-dgnb) —

If Evkeeza Isn't Approved by Aetna CVS Health in Ohio: Formulary Alternatives & Exception Paths

Answer Box: If Aetna CVS Health denies Evkeeza (evinacumab-dgnb) for homozygous familial hypercholesterolemia (HoFH) in Ohio, you have two main paths: try formulary alternatives like Repatha (evolocumab) or Juxtapid (lomitapide), or appeal for a formulary exception. Aetna prefers PCSK9 inhibitors as first-line specialty therapy, requiring documented failure of maximally tolerated statins and ezetimibe. File internal appeals within 180 days, then external review through Ohio's Independent Review Organization if denied. Start by requesting Aetna's HoFH prior authorization forms through your provider portal.

Table of Contents

When Formulary Alternatives Make Sense

Before pursuing a lengthy formulary exception appeal for Evkeeza, consider whether Aetna's preferred alternatives might work for your specific case. This approach makes sense when:

  • You haven't tried Aetna's preferred PCSK9 inhibitors (Repatha or Praluent) for at least 3 months
  • Your HoFH mutation type is receptor-defective rather than receptor-null (meaning some residual LDL receptor function remains)
  • You need faster access to treatment while pursuing an Evkeeza exception
  • Your current LDL-C levels are ≥100 mg/dL despite maximally tolerated background therapy

Key considerations: Even in HoFH, PCSK9 inhibitors and other receptor-dependent therapies may provide 15-30% additional LDL-C reduction in patients with some residual receptor function. For receptor-null mutations, these alternatives are less effective, making Evkeeza or lomitapide more appropriate choices.

Aetna's Preferred HoFH Alternatives

Based on Aetna's 2025 formulary policies, the insurer follows a clear preference hierarchy for HoFH treatment:

First-Line Specialty Options

  1. Repatha (evolocumab) - Primary preferred PCSK9 inhibitor
  2. Praluent (alirocumab) - Requires documented Repatha failure/intolerance

Second-Line Options

  1. Juxtapid (lomitapide) - For severe cases with PCSK9 inhibitor failure
  2. Evkeeza (evinacumab-dgnb) - Non-formulary, requires exception

Notably absent from Aetna's preferred lists are mipomersen (discontinued) and LDL apheresis as standalone alternatives, though apheresis may be covered as adjunctive therapy.

Coverage at a Glance: Alternative Options

Alternative Formulary Status Prior Auth Required Step Therapy Key Requirements Timeline
Repatha Preferred specialty Yes Statin + ezetimibe failure HoFH diagnosis, LDL-C ≥100 mg/dL 30-45 days
Praluent Covered specialty Yes Repatha failure required Same as Repatha + Repatha intolerance 30-45 days
Juxtapid Covered specialty Yes PCSK9 inhibitor failure REMS enrollment, liver monitoring 30-45 days
Evkeeza Non-formulary Yes All above failed Formulary exception needed 60-90 days

Source: Aetna Specialty Drug List 2025

Pros and Cons of Each Alternative

Repatha (evolocumab)

Pros:

  • Fastest Aetna approval path for HoFH
  • Self-administered subcutaneous injection (every 2 weeks or monthly)
  • Well-established safety profile
  • No special monitoring requirements

Cons:

  • Limited effectiveness in receptor-null HoFH (typically 15-25% LDL-C reduction)
  • May not achieve target LDL-C levels in severe cases
  • Requires ongoing background statin therapy when tolerated

Praluent (alirocumab)

Pros:

  • Similar efficacy to Repatha in receptor-defective HoFH
  • Self-administered subcutaneous injection
  • Alternative if Repatha causes injection site reactions

Cons:

  • Requires documented Repatha failure for Aetna approval
  • Similar limited effectiveness in receptor-null cases
  • Additional step therapy hurdle

Juxtapid (lomitapide)

Pros:

  • Significant LDL-C reduction (often 40-50%) regardless of receptor function
  • Oral medication (daily dosing)
  • Effective in both receptor-defective and receptor-null HoFH

Cons:

  • FDA REMS program requirements - prescriber and pharmacy enrollment needed
  • Frequent liver monitoring (monthly during titration, quarterly maintenance)
  • Gastrointestinal side effects requiring strict low-fat diet
  • Drug interactions with CYP3A4 inhibitors
From our advocates: We've seen Ohio patients successfully transition from denied Evkeeza to approved Juxtapid within 6 weeks by having their lipidologist document specific LDL-C targets that couldn't be met with PCSK9 inhibitors alone. The key was emphasizing receptor-null genotype and providing detailed prior therapy failure records.

Formulary Exception Strategy for Evkeeza

When alternatives aren't appropriate or effective, pursue an Evkeeza formulary exception with these evidence elements:

Medical Necessity Documentation

Your prescriber's letter should include:

  • HoFH diagnosis confirmation: Genetic testing results or clinical criteria (untreated LDL-C >500 mg/dL, family history, physical findings)
  • Current LDL-C levels: Recent labs showing inadequate control despite maximally tolerated therapy
  • Prior therapy failures: Documented trials of high-dose statin, ezetimibe, and PCSK9 inhibitor for ≥3 months each
  • Contraindications to alternatives: Specific reasons why Repatha, Praluent, or lomitapide aren't suitable
  • Treatment goals: Target LDL-C levels and cardiovascular risk reduction objectives

Supporting Evidence

  • Recent lipid panels and genetic testing reports
  • Prior authorization denial letters for alternatives (if applicable)
  • Specialist consultation notes (cardiologist or lipidologist)
  • FDA labeling supporting Evkeeza's unique mechanism

Counterforce Health can help analyze your denial letter and identify specific gaps in your exception request, streamlining the appeal process with targeted evidence.

Appeals Playbook for Ohio

Internal Appeals (Required First Step)

  • Deadline: 180 days from denial date
  • Timeline: Standard decision within 30 days; expedited within 72 hours if physician certifies health jeopardy
  • Submission: Written request to Aetna appeals department with supporting documentation
  • Required documents: Original denial letter, updated medical records, specialist recommendations

External Review (After Internal Denial)

Ohio residents have strong external review rights through the Ohio Department of Insurance:

  • Deadline: 180 days from final internal denial
  • Cost: Free to members
  • Process: Independent Review Organization (IRO) with board-certified physician in relevant specialty
  • Timeline: 30 days standard, 72 hours expedited
  • Binding decision: If approved, Aetna must cover the treatment

Contact Ohio DOI: 1-800-686-1526 for assistance with external review eligibility or process questions.

Self-Funded Plan Considerations

If your Aetna plan is self-funded through a large employer, federal ERISA rules apply instead of Ohio state law. However, many self-funded plans voluntarily use external review processes similar to Ohio's requirements.

Switching Between HoFH Therapies

From Evkeeza to Alternatives

If switching from denied Evkeeza to an approved alternative:

  1. Timing coordination: Schedule new therapy to minimize LDL-C rebound
  2. Documentation: Record baseline LDL-C levels before starting alternative
  3. Monitoring plan: Establish follow-up schedule to assess effectiveness
  4. CVS Specialty coordination: Ensure specialty pharmacy enrollment for new medication

From Alternatives to Evkeeza

When pursuing Evkeeza after trying alternatives:

  1. Document everything: LDL-C levels, side effects, adherence issues
  2. Minimum trial periods: Generally 3 months for each alternative unless contraindicated
  3. Quantify inadequate response: Specific LDL-C targets not met despite optimal dosing

Re-trying for Evkeeza Later

If your initial Evkeeza exception is denied, strengthen future requests by:

Building Your Case

  • Complete alternative trials: Document 3-month trials of Repatha and either Praluent or lomitapide
  • Quantify failures: Specific LDL-C levels achieved vs. targets needed
  • Safety issues: Document any significant side effects or contraindications
  • Compliance verification: Pharmacy records showing adherence to prescribed regimens

Timing Considerations

  • Wait for significant clinical changes (new cardiovascular events, progression of disease)
  • Annual policy updates may change formulary status
  • New clinical data or guideline updates supporting Evkeeza use

Working with Counterforce Health's platform during alternative therapy trials can help systematically document the evidence needed for a stronger future Evkeeza request.

FAQ: Common Questions

How long does Aetna prior authorization take for HoFH medications in Ohio? Standard decisions take 30-45 days. Expedited requests (when physician certifies urgent medical need) are decided within 72 hours.

What if Evkeeza is completely non-formulary on my plan? You can still request a formulary exception with medical necessity documentation. Ohio's external review process applies to medical necessity denials, even for non-formulary drugs.

Do I need to try every alternative before requesting Evkeeza? Not necessarily. If you have documented contraindications or genetic factors making alternatives inappropriate, these can be used to justify bypassing step therapy.

Can I appeal if my plan changes and drops Evkeeza coverage? Yes. Mid-year formulary changes that affect your current therapy typically trigger special appeal rights and transition periods.

Does my HoFH genotype matter for approval chances? Yes. Receptor-null mutations provide stronger justification for Evkeeza since PCSK9 inhibitors are less effective. Include genetic testing results in your request.

How do I know if my Aetna plan is self-funded vs. fully insured? Check your insurance card or contact Aetna member services. Self-funded plans follow federal ERISA rules; fully insured plans follow Ohio state insurance law for appeals.

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Always consult with your healthcare provider and insurance company for guidance specific to your situation. For questions about Ohio insurance regulations, contact the Ohio Department of Insurance at 1-800-686-1526.

Sources & Further Reading

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.